KPMA backs bioequivalence testing stern measures on generic data fabrication

Published: 2008-02-26 07:00:00

Updated: 2008-02-26 07:00:00

The Korea Food and Drug Administration says its harsh dispositions to cancel the licenses of pharmaceutical firms' six generic drugs on charge of bioequivalence data fabrication are deemed undisputable.

The health watchdog points out these pharmaceutical manufacturers are solely responsible fo...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK